Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-26 @ 11:11 AM
Ignite Modification Date: 2025-12-26 @ 11:11 AM
NCT ID: NCT02485028
Eligibility Criteria: Inclusion Criteria: * Healthy male adults aged between 19 and 55 * Body mass index (BMI) in the range of 19 to 27 kg/m2 * Understand the requirements of the study and voluntarily consent to participate in the study * Available for the entire study period Exclusion Criteria: * Subject has a history such as liver diseases, kidneys, digestive system, respiratory system, endocrine system, nervous psychiatric, blood, cancer, cardiovascular diseases * Subject with clinically significant vital signs (sitting position blood pressure) (90 mmHg \> systolic blood pressure ≥ 140 mmHg, 60 mmHg \> diastolic blood pressure ≥ 90 mmHg) * History of drug abuse * History of caffeine, alcohol, smoking abuse * caffeine(coffee,tea,coke)\> 4cups/day * smoking \> 10 cigarettes/day * alcohol \> 140g/week * Consumption of any grapefruit or grapefruit-containing juices over 1 cup a day * Previously donate whole blood within 60 days or component blood within 30 days * Subject has taken drugs which affects the ADME of investigational products * Subject with known for hypersensitivity reactions to mirodenafil/ dapoxetine or other drugs * Inadequate laboratory test result: * AST(SGOT) or ALT(SGPT) or total bilirubin \> 1.5 x upper limit of normal range * eGFR \< lower limit of normal range * Subject considered as unsuitable based on medical judgement by investigators
Healthy Volunteers: True
Sex: MALE
Minimum Age: 19 Years
Maximum Age: 55 Years
Study: NCT02485028
Study Brief:
Protocol Section: NCT02485028